摘要
探讨替米沙坦与厄贝沙坦治疗高血压的疗效和安全性。选择2020年1月—2024年12月西安理工大学校医院门诊诊治的76例原发性高血压患者为研究对象,经随机数字抽样法将其分为厄贝组和替米组,每组各38例。替米组采用替米沙坦治疗,厄贝组采用厄贝沙坦治疗,对比两组患者的降压效果和血压变异性,并观察患者肾功能状态及用药安全性。结果显示,治疗后,替米组收缩压、舒张压显著低于厄贝组(P<0.05)。治疗后,替米组24h DCV、24h SCV、24h mDBP和24h mSBP水平均显著低于厄贝组(P<0.05)。治疗后,替米组不良反应发生率(10.53%)与厄贝组(13.15%)比较,无统计学差异(P>0.05)。研究发现,两种血管紧张素Ⅱ受体阻断剂均可显著改善患者血压水平及肾功能指标,且不良反应发生率均较低,安全性可靠。与厄贝沙坦比较,替米沙坦的降压效果更显著,可降低患者的血压变异性。
This study explores the efficacy and safety of telmisartan and irbesartan in treating hypertension.A total of 76 patients with essential hypertension treated at the University Hospital of Xi’an University of Technology from January 2020 to December 2024 were enrolled and randomly divided into an irbesartan group and a telmisartan group(38 cases each).The telmisartan group received telmisartan,while the irbesartan group received irbesartan.Antihypertensive effects,blood pressure variability,renal function,and safety were compared between groups.After treatment,the telmisartan group had signifi cantly lower systolic blood pressure and diastolic blood pressure than the irbesartan group(P<0.05).The telmisartan group also showed signifi cantly lower 24h diastolic coefficient of variation(DCV),24h systolic coefficient of variation(SCV),24h mean diastolic blood pressure(mDBP),and 24h mean systolic blood pressure(mSBP)than the irbesartan group(P<0.05).No signifi cant difference was found in adverse reaction rates between groups(10.53%vs.13.15%,P>0.05).Both angiotensinⅡreceptor blockers signifi cantly improved blood pressure and renal function with low adverse reaction rates.Compared with irbesartan,telmisartan showed more pronounced antihypertensive effects and reduced blood pressure variability.
作者
唐杰
李燕妮
梁妍
王锦程
Tang Jie;Li Yanni;Liang Yan;Wang Jincheng(Department of Internal Medicine,University Hospital of Xi’an University of Technology,Xi’an,Shaanxi 710000;Department of Traditional Chinese Medicine,University Hospital of Xi’an University of Technology,Xi’an,Shaanxi 710000)
出处
《科技与健康》
2025年第11期109-112,共4页
Technology and Health
